Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	16.26M +44.7%
Revenue (ttm)	n/a +12.8%
Net Income	n/a
EPS	n/a
Shares Out	2.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,417
Open	6.32
Previous Close	6.24
Day's Range	6.10 - 6.42
52-Week Range	3.10 - 7.78
Beta	0.82
Analysts	Buy
Price Target	41.00 (+551.83%)
Est. Earnings	Nov 16, 2026

About BOLT

Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Bol...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 23
• Stock Exchange: Nasdaq
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2025, Bolt Biotherapeutics's revenue was $7.70 million, an increase of 0.07% compared to the previous year's $7.69 million. Losses were -$33.38 million, -47.12% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price target is $41.0, which is an increase of 551.83% from the latest price.

Price Target

$41.0

(551.83% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 3, 2026

Data Sources Report a data error